Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Proof of Concept Study to Assess the Differential Effects of Chronic Beta-blockade (Celiprolol Versus Bisoprolol) on Cardiopulmonary Outcomes at Rest and During Exercise in Chronic Obstructive Pulmonary Disease
What are the differential effects of beta-blockers on lung and heart function during exercise
in chronic obstructive pulmonary disease (COPD)? COPD is a major cause of illness and death.
Not only do these individuals suffer from lung disease, but COPD often leads to other
illnesses, particularly heart disease. Beta-blockers very successfully treat heart disease.
It is therefore logical that one would want to use this treatment in COPD patients with heart
disease too. However, there has always been concern that beta-blockers could cause
significant problems in COPD by worsening lung function, as these can have the opposite
effect to inhalers used to treat COPD that open up airways. Pointedly, there is increasing
evidence that despite this problem, COPD patients who have been prescribed beta-blockers have
been shown to gain benefit particularly in terms of preventing death.
In this study, the investigators therefore want to examine which beta-blocker might be the
safest for COPD patients, as each work slightly differently. Some beta-blockers may have a
more beneficial effect on airways than others, whilst still benefitting the heart. The
investigators will study two different beta-blockers; one that potentially narrows airways
and one that potentially opens airways. The investigators will be using cardiopulmonary
exercise testing (an exercise bike that measures both heart and lung function during
exercise) to look for differences between both beta-blockers primarily in terms of lung
function but also with information about the heart. The investigators will recruit people
with moderate to severe COPD who are able to complete a cycle exercise test through their
respiratory research department. The study will last for 10-12 weeks with 5 main visits to
the department for serial exercise tests, breathing tests, simple heart function tests and
simple blood tests that will tell the investigators what other effects these beta-blockers
are having on the heart and lungs.
Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death. In fact,
by 2020, the World Health Organization predicts that COPD will become the third leading cause
of death (currently fourth), and the fifth leading cause of disability (currently twelfth)
worldwide. COPD and cardiovascular (heart) disease are intertwined due to the associated risk
of smoking related atherosclerosis. Beta-blockers are generally avoided in COPD patients due
to the associated risk of worsening lung function and acute bronchospasm (airway narrowing)
due to beta-2-receptor blockade. Despite these concerns a recent Cochrane review has shown
that chronic beta-blockade with "cardioselective" beta-blockers (for example bisoprolol) that
preferentially block beta-1 (mostly heart) over beta-2 (mostly airway) receptors are well
tolerated with less beta-2-blockade and subsequently less bronchospasm.
Furthermore, observational studies evaluating the impact of beta-blocker use in COPD patients
have shown benefits on survival with beta-blockers. We have published retrospective data from
5,977 patients with COPD with a mean follow up of 4.35 years, showing that patients using
beta-blockers (88% cardio-selective) produced a 22% overall reduction in death as well as
significant reductions in respiratory hospital admissions and oral steroid use.
Beta-blockers are pharmacologically different and there now needs to be an assessment of the
clinical consequences of different beta-blockers in COPD. Despite being "cardioselective",
bisoprolol still shows significant beta-2-receptor blockade at usual treatment doses, which
results in a significant worsening in Forced Expiratory Volume in 1second - FEV1 (a major
marker of lung function) following chronic use. Celiprolol however is a unique beta-blocker
which in addition to its beta-1-receptor blockade has partial beta-2-agonist activity and
therefore it does not cause bronchoconstriction or interact with short and long acting
beta-agonist inhalers which are the mainstay of COPD treatment. Thus celiprolol might confer
an ideal profile for use in COPD (i.e. good for heart and not detrimental to lungs),
especially in more severe patients where even a small fall in FEV1 might have significant
consequences on their breathing and exercise capacity.
Poor exercise tolerance is associated with worsening quality of life and increased risk of
death and thus provides a valuable surrogate marker of death. Worsening respiratory symptoms
in COPD patients are more commonly seen on exertion than at rest, and associated with
abnormal increases in lung volumes where air that is breathed in becomes trapped and cannot
completely escape when breathing out (dynamic hyperinflation).
Cardiopulmonary exercise testing provides a global assessment of both respiratory (lung) and
cardiovascular (heart) response to exercise. Whilst studies have shown a worsening of dynamic
hyperinflation with bisoprolol, due to their differing pharmacological properties it might be
that celiprolol will not result in worsening dynamic hyperinflation, whilst also
demonstrating improvement in cardiovascular outcomes such as stroke volume (the pump function
of the heart) and heart rate recovery following exercise. Whether these effects result in an
improved exercise tolerance is unknown. Another interesting property of celiprolol is reduced
cholesterol and increased High Density Lipoprotein (HDL) fraction conferred by partial
beta-2-agonist activity. We will also measure serum markers of cardiac dysfunction (B-type
Natriuretic Peptide (BNP) and Galectin-3) and their response to beta-blockade which to the
investigators' knowledge has never been performed in a COPD study.
With regards to measuring cardiovascular outcomes of cardiac output and stroke volume, the
investigators plan to use a novel non-invasive monitor which is based on the phenomenon of
bioreactance that occurs when a small alternating current is passed through the chest. To the
investigators' knowledge this device has never been used when assessing cardiovascular
response to beta-blockers during exercise, but it is safe and easy to perform at the same
time as the standard exercise test.
The investigators therefore wish to assess the relative effects of both celiprolol and
bisoprolol in COPD patients and establish whether the proposed benefits on survival with
beta-blockers in COPD are reflected in improved cardiovascular and respiratory response to
exercise and importantly exercise tolerance. The investigators also want to see if celiprolol
is superior to bisoprolol on these markers (particularly lung function) as described above.
The information gathered from this study will be invaluable as it will provide further
information about the effects of beta-blockers in COPD and will be used to pump-prime larger
long-term studies examining the effects of beta-blockers on survival in many more COPD
patients.
Hypothesis The null hypothesis is that there is no difference between bisoprolol and
celiprolol in terms of cardiorespiratory outcomes during incremental exercise testing in
patients with moderate to severe COPD - specifically no difference in the proposed primary
outcome measure of dynamic hyperinflation during cycle endurance testing.
Design The investigators have chosen a randomised crossover design to answer this question
because it is unknown which, if either, beta-blocker might be better for lung function and
exercise capacity in moderate to severe COPD patients. The crossover design allows the use of
the same patients as their own comparators, thus allowing the investigators to expose fewer
patients to these medications with the same statistical power as a parallel group study
(different patients in each group). Each participant will therefore receive both treatments
in sequence but with their initial one decided at random using a randomisation algorithm.
Importantly the investigators have not used a placebo control arm here, as it is already
known that beta-blockers are of benefit to COPD patients (particularly those with
cardiovascular disease) whereas placebo provides no benefit. In other words the investigators
are drilling down to see which particular medication has the most beneficial therapeutic
profile. The justification for using open-label beta-blockers is that this is a pilot study
and it helps to keep the overall costs of the study down at this stage of investigation.
Methods The investigators will perform a randomised, cross-over, open label trial of
bisoprolol versus celiprolol with 10 people who have moderate to severe COPD. The study will
last between 10-12 weeks for each person. Potential participants will be recruited from our
existing database of volunteers with COPD, contacted either by telephone, email or post and
invited to participate. Those invited will receive a written patient information document
detailing the requirements of the study and the extent of their participation before
attending for a screening visit. Participants will be given at least 24hours to read the
information document before deciding whether or not they agree to be screened. The study will
include 5 visits to the department (including the screening visit) for the various tests
outlined below. Each visit may last for around 3 hours. If participants agree to coming along
for a screening visit, they will be asked to withhold any long-acting bronchodilators for
48hours and short acting bronchodilators for 6 hours as is standard practice when confirming
the diagnosis of airway obstruction / COPD using clinical pulmonary function measurements.
Screening Visit At the screening visit, the information document will be discussed with the
participant and written informed consent will be obtained if they agree to take part in the
study. The following will then be performed: a general medical examination by a doctor; a
pregnancy test for all females; lung function measurements (spirometry, impulse oscillometry,
reversibility to salbutamol); heart function measurements (resting ECG [electrocardiogram],
echocardiogram where possible if not done in last year); vital signs (oxygen levels, blood
pressure, pulse); 'practice' cardiopulmonary exercise test (to confirm ability to cycle and
to counter any 'learning effect' from future baseline exercise test); baseline blood tests.
Inhaler technique will also be assessed and confirmed adequate. Participants found to be
eligible for the remainder of the study after these tests will proceed through a 1 week
run-in period on their usual medications before coming back for the first (baseline) visit.
Those who do not fulfil the study criteria will continue on their usual medication and their
General Practitioner (GP) informed of any medically relevant data. Eligible participants will
be provided with portable monitors to measure their own lung function, pulse and oxygen
saturations at home twice daily to be recorded in a daily diary which will also include
details of their reliever use and symptoms. This diary will be kept throughout the study.
Study visits Prior to participants attending for their first (baseline) study visit they will
be asked to only withhold their short-acting reliever inhaler for 6 hours. Participants will
not be required to withhold any long-acting bronchodilators for study visits as we are
assessing any effects of the beta-blockers in addition to these standard treatments and we
will have confirmed the diagnosis of COPD at the screening visit. Diary cards will be
reviewed and the following measurements will be recorded at visit 1: resting lung function
(impulse oscillometry, spirometry, whole body plethysmography); resting ECG; vital signs; St
George's Respiratory Questionnaire (disease specific quality of life questionnaire); blood
sample (BNP, Galectin, Cholesterol/HDL, Creatine Kinase (CK), Potassium); cardiopulmonary
exercise test. Provided the participant's measurements still correspond to the inclusion and
exclusion criteria for the study, they will be randomised to one of the two beta-blocker
treatments: Bisoprolol (2.5mg daily for 2 weeks, then 5mg daily for approximately 2 weeks) OR
Celiprolol (200mg daily for 2 weeks, then 400mg daily for approximately 2 weeks).
Beta-blockers will be up-titrated at home after 2 weeks with advice about contacting us if
side effects develop. Participants will be contacted both before and after this up titration
either by telephone or email. However, if adverse effects occur on the higher dose, then
participants will be allowed to drop back to the lower dose for the remainder of the study
period. At the end of each treatment period, study measures will be repeated as above. After
visit 2 participants will have an approximately 1 week washout period prior to being given
the alternate beta-blocker treatment.
End of study After visit 4 each participant will have completed the study and they will be
returned to their usual medications. The overall study will be complete when the last
enrolled participant completes the protocol.
Analysis and final reporting All analyses will be performed at the end of the study. There
will be no interim analysis. The report will be published in a high impact peer reviewed
journal.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|